Dr. Douglas’ study “Teprotumumab for Thyroid-Associated Ophthalmopathy” was recently published in the New England Journal of Medicine. The U.S. Food and Drug Administration (FDA) designated this drug as a “breakthrough” therapy, which is only given to a couple of drugs each year that is so important to changing the field of treatment for patients.Dr. Douglas lead twenty-two centers as the principal investigator of this trial and represent the largest trial of a biologic ever for Thyroid Eye Disease. A follow-up clinical trial is currently underway and is expected to be completed in 2018.
What does Teprotumumab do?
For those that suffer from bulging of the eyes due to Thyroid Eye Disease, Teprotumumab is the first medicine of its kind that may provide therapy for avoiding complex surgery and preventing vision loss. Most patients in the initial trial who received the active drug instead of a placebo had reduced eye-bulging, eye pain and swelling and improved quality of life. For some, the therapeutic benefit occurred within six weeks of intravenous infusions of the drug.
Am I A Candidate For The Teprotumumab Trial?
Candidates must meet the following basic eligibility criteria:
18-75 years of age
Onset of active Thyroid Eye Disease symptoms within 9 months
Does not require immediate surgical ophthalmological intervention
Has not had previous orbital irradiation or surgery for Thyroid Eye Disease
Must not be pregnant or lactating
If you do not fit these criteria, we can still help! There are other options available to address your concerns. The easiest way to find out more about the Teprotumumab trial is to call us today at 310.657.4302.
I Don’t Live In Southern California. Can I Still Participate?
Of course! For those that are located outside of Southern California, Dr. Douglas offers convenient Skype consultations so you can learn more about the trial, discover whether you are a candidate for therapy, or to discuss your concerns. To find out more information, call us today at 310.657.4302.
Watch Dr. Douglas discuss Teprotumumab
Description
In a PSA for CNN in Southern California, Dr. Raymond Douglas discusses the benefits of the new FDA approved breakthrough therapy Teprotumumab for Thyroid Eye Disease.
Dr. Raymond Douglas is honored to announce that his new study “Teprotumumab for Thyroid-Associated Ophthalmopathy“ has been published in the New England Journal of Medicine. The FDA has designated this drug as a “breakthrough” therapy. This designation is only given to a couple of drugs each year and is reserved for drugs that are so important and beneficial to changing the field of treatment for patients. Dr. Douglas was the principle investigator of all the research centers and the trial. Twenty-two centers were involved and this represents the largest trial of biologic ever in this disease.
This is the first medicine that can take the place of surgery for thyroid eye disease patients and is the first and only medicine that has ever been shown to reverse the disease. Dr. Douglas will be directing continued trials in Los Angeles (the only center on the West Coast).
To find out if you are a candidate for this treatment, call us today – 310.567.4354.
